Mabion S.A.

Mabion S.A. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Mabion S.A. is a Polish biopharmaceutical CDMO providing extensive drug development and biomanufacturing services to pharmaceutical and Biotech companies globally. We offer services for clinical and commercial manufacture of recombinant protein therapeutics, including process and analytical development services, GMP manufacture of Drug Substance (from small scale up to 4 x 2.000 liter single-use bioreactor sizes), GMP manufacture of Drug Product in our state-of-the-art filling line and an extensive set of analytics and QC tests. This is supported by a robust quality assurance and regulatory affairs department. In addition to our regular CDMO offering, Mabion also took part in the global fight against the coronavirus pandemic by signing a record contract with Novavax Inc. in October 2021 for the commercial production of the antigen for their COVID-19 vaccine. This partnership has proven to be very successful, leading to several subsequent additional services offered by Mabion, augmenting the main commercial-scale manufacturing contract. We aim to establish ourselves as a key global player in the global contract manufacturing and contract drug development market offering a broad range of high-quality integrated services to the Biotech and pharmaceutical market. Mabion is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu

Company Details

Employees
179
Founded
-
Address
Ul. Gen. Mariana Langiewicza 60, Konstantynów Łódzki,łódzkie,poland 95-050,poland
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Konstantynów Łódzki, łódzkie, Poland
Looking for a particular Mabion S.A. employee's phone or email?

Mabion S.a. Questions

News

Biosimilars Expand Access to Essential Biological Therapies - HIT Consultant

Biosimilars Expand Access to Essential Biological Therapies HIT Consultant

Mabion launches €500,000 CDMO services contest at BIO - BioProcess International

Mabion launches €500,000 CDMO services contest at BIO BioProcess International

Why Mabion S.A. (272) stock appeals to dividend investors - Weekly Investment Report & Stepwise Trade Signal Implementation - Trung tâm Dự báo KTTV quốc gia

Why Mabion S.A. (272) stock appeals to dividend investors - Weekly Investment Report & Stepwise Trade Signal Implementation Trung tâm Dự báo KTTV quốc gia

Mabion Launches €500,000 Services Contest to Support Next-Gen Oncology Advances - Genetic Engineering and Biotechnology News

Mabion Launches €500,000 Services Contest to Support Next-Gen Oncology Advances Genetic Engineering and Biotechnology News

Mabion Launches €500,000 Oncology Services Contest - Contract Pharma

Mabion Launches €500,000 Oncology Services Contest Contract Pharma

Mabion Says Krzysztof Kaczmarczyk Dismissed As CEO - TradingView

Mabion Says Krzysztof Kaczmarczyk Dismissed As CEO TradingView

Sentiment Review: Why Mabion S.A. (272) stock appeals to dividend investors - Market Trend Report & Free Risk Controlled Daily Trade Plans - Trung tâm Dự báo KTTV quốc gia

Sentiment Review: Why Mabion S.A. (272) stock appeals to dividend investors - Market Trend Report & Free Risk Controlled Daily Trade Plans Trung tâm Dự báo KTTV quốc gia

Mabion, NovalGen Partner to Bring NVG-222 to Market - Contract Pharma

Mabion, NovalGen Partner to Bring NVG-222 to Market Contract Pharma

Mabion withdraws application for rituximab biosimilar in EU - Generics and Biosimilars Initiative

Mabion withdraws application for rituximab biosimilar in EU Generics and Biosimilars Initiative

Will Mabion S.A. (272) stock benefit from infrastructure bill - 2025 Performance Recap & Technical Pattern Alert System - newser.com

Will Mabion S.A. (272) stock benefit from infrastructure bill - 2025 Performance Recap & Technical Pattern Alert System newser.com

Navigating the Complexities of Preclinical and Clinical Trials - HIT Consultant

Navigating the Complexities of Preclinical and Clinical Trials HIT Consultant

Monoclonal antibody biosimilars for cancer treatment - ScienceDirect.com

Monoclonal antibody biosimilars for cancer treatment ScienceDirect.com

Is Mabion S.A. (272) stock a buy on weakness - 2025 Institutional Moves & Growth Focused Entry Point Reports - newser.com

Is Mabion S.A. (272) stock a buy on weakness - 2025 Institutional Moves & Growth Focused Entry Point Reports newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - July 2025 Macro Moves & Accurate Intraday Trade Tips - newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - July 2025 Macro Moves & Accurate Intraday Trade Tips newser.com

Will Mabion S.A. (272) stock test record highs in 2025 - July 2025 Action & Smart Swing Trading Techniques - newser.com

Will Mabion S.A. (272) stock test record highs in 2025 - July 2025 Action & Smart Swing Trading Techniques newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - Quarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - Quarterly Trade Summary & Step-by-Step Trade Execution Guides newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - July 2025 Levels & Precise Buy Zone Identification - newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - July 2025 Levels & Precise Buy Zone Identification newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - Trade Exit Summary & Daily Growth Stock Tips - newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - Trade Exit Summary & Daily Growth Stock Tips newser.com

Is Mabion S.A. (272) stock a buy on weakness - July 2025 Macro Moves & Weekly High Return Opportunities - newser.com

Is Mabion S.A. (272) stock a buy on weakness - July 2025 Macro Moves & Weekly High Return Opportunities newser.com

Will Mabion S.A. (272) stock benefit from infrastructure bill - 2025 Volatility Report & Smart Money Movement Alerts - newser.com

Will Mabion S.A. (272) stock benefit from infrastructure bill - 2025 Volatility Report & Smart Money Movement Alerts newser.com

KC breaks ground on new affordable apartments off Troost named for neighborhood pastor - Kansas City Star

KC breaks ground on new affordable apartments off Troost named for neighborhood pastor Kansas City Star

How Mabion S.A. (272) stock reacts to fiscal policies - July 2025 Summary & Fast Momentum Entry Tips - newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - July 2025 Summary & Fast Momentum Entry Tips newser.com

Will Mabion S.A. (272) stock test record highs in 2025 - Portfolio Update Summary & Safe Capital Investment Plans - newser.com

Will Mabion S.A. (272) stock test record highs in 2025 - Portfolio Update Summary & Safe Capital Investment Plans newser.com

New project in Kansas City's Beacon Hill looks to provide affordable housing - KSHB 41 Kansas City

New project in Kansas City's Beacon Hill looks to provide affordable housing KSHB 41 Kansas City

Is Mabion S.A. (272) stock a buy on weakness - July 2025 Catalysts & Weekly High Momentum Picks - newser.com

Is Mabion S.A. (272) stock a buy on weakness - July 2025 Catalysts & Weekly High Momentum Picks newser.com

Will Mabion S.A. (272) stock benefit from infrastructure bill - Trade Volume Summary & Free Fast Entry Momentum Trade Alerts - newser.com

Will Mabion S.A. (272) stock benefit from infrastructure bill - Trade Volume Summary & Free Fast Entry Momentum Trade Alerts newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - Short Setup & Accurate Technical Buy Alerts - newser.com

How Mabion S.A. (272) stock reacts to fiscal policies - Short Setup & Accurate Technical Buy Alerts newser.com

Rituximab biosimilar submitted to EMA and Rituxan gains extra indication - Generics and Biosimilars Initiative

Rituximab biosimilar submitted to EMA and Rituxan gains extra indication Generics and Biosimilars Initiative

Biosimilars of rituximab - Generics and Biosimilars Initiative

Biosimilars of rituximab Generics and Biosimilars Initiative

Former Emporia State football player dead in apparent homicide-suicide in Olathe - The Topeka Capital-Journal

Former Emporia State football player dead in apparent homicide-suicide in Olathe The Topeka Capital-Journal

Wife who died in Olathe murder-suicide had filed for divorce - Kansas City Star

Wife who died in Olathe murder-suicide had filed for divorce Kansas City Star

Olathe police believe former ESU football player killed estranged wife, then himself - The Topeka Capital-Journal

Olathe police believe former ESU football player killed estranged wife, then himself The Topeka Capital-Journal

Sister of Olathe murder-suicide victim says violence was never imagined - Kansas City Star

Sister of Olathe murder-suicide victim says violence was never imagined Kansas City Star

Friends, community shocked and struggling to make sense of Olathe murder-suicide - FOX4KC.com

Friends, community shocked and struggling to make sense of Olathe murder-suicide FOX4KC.com

Olathe PD: Husband shot wife in murder-suicide - KSHB 41 Kansas City

Olathe PD: Husband shot wife in murder-suicide KSHB 41 Kansas City

Top Mabion S.A. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant